WebMar 13, 2024 · Their share performances varied on Monday, with Broncus Holding Corporation advancing 4% while CStone Pharmaceuticals was down 2.2%. Further supporting sentiment, China reported unexpectedly strong credit growth for February, with money supply expanding at the fastest pace in nearly 7 years, as Beijing looked to … WebCSTONE PHARMACEUTICALS REGISTERED AKTIE Profil - hier finden Sie alle Informationen über CSTONE PHARMACEUTICALS REGISTERED AKTIE wie z.B. Management, Profil, Aktionärsstruktur und Bilanzdaten.
2616 CStone Pharmaceuticals Stock Price & News - WSJ
WebCStone Pharmaceuticals is a biopharma company focused on developing and commercializing innovative immuno-oncology and molecularly targeted drugs to address significant unmet medical needs for cancer patients in … WebSuzhou, China, March 20th, 2024--CStone Pharmaceuticals (HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology ther... 15 2024-03. CStone Pharmaceuticals Reports 2024 Annual Results and Business Updates . great harwood cheese shops
CStone Pharmaceuticals - Funding, Financials, Valuation
Web中国苏州,2024年2月23日—基石药业(香港联交所代码:2616),一家专注于研究开发及商业化创新肿瘤免疫疗法... 基石药业荣获“头部力量·中国医药高质量发展成果企业”及“成果品牌”两项大奖. 基石药业宣布精准治疗药物 … WebFunding. CStone Pharmaceuticals has raised a total of $410M in funding over 2 rounds. Their latest funding was raised on May 9, 2024 from a Series B round. CStone Pharmaceuticals is registered under the ticker HKG:2616 . Their stock opened with HK$12.00 in its Feb 25, 2024 IPO. WebJun 7, 2024 · CStone Pharmaceuticals (OTCPK:CSPHF) (2616.HK) revenue fell 77% last year and its net loss climbed, as the Chinese drug company saw one-off license fees decline sharply and marketing costs to ... float and board level indicator